Paratek Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
75 Park Plaza, 4 Th Floor, Boston, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Transcept Pharmaceuticals Inc (to 10/30/2014), NOVACEA INC (to 1/20/2009)
Latest financial report
10-Q - Q2 2023 - Aug 3, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % -67.9%
Quick Ratio 20.1 % -47.4%
Debt-to-equity -186 % +20.5%
Return On Equity 34.5 % -47.6%
Return On Assets -40.1 % +18.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57.3M shares +4.48%
Common Stock, Shares, Outstanding 57.3M shares +4.57%
Common Stock, Value, Issued 57K USD +3.64%
Weighted Average Number of Shares Outstanding, Basic 57.3M shares +8.03%
Weighted Average Number of Shares Outstanding, Diluted 57.3M shares +8.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 177M USD +108%
Cost of Revenue 25.3M USD +45.6%
Costs and Expenses 222M USD +24%
Operating Income (Loss) -44.5M USD +34.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -14.5M USD +17.7%
Income Tax Expense (Benefit) 169K USD -71.8%
Net Income (Loss) Attributable to Parent -62.7M USD +27%
Earnings Per Share, Basic -1.09 USD/shares +36.3%
Earnings Per Share, Diluted -1.09 USD/shares +36.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.7M USD +8.05%
Cash, Cash Equivalents, and Short-term Investments 42.7M USD -38.5%
Accounts Receivable, after Allowance for Credit Loss, Current 42.3M USD +48.3%
Inventory, Net 11.4M USD -12.8%
Assets, Current 105M USD -17.6%
Property, Plant and Equipment, Net 554K USD -22.2%
Operating Lease, Right-of-Use Asset 1.65M USD +21.7%
Goodwill 829K USD 0%
Other Assets, Noncurrent 1.16M USD +368%
Assets 146M USD -10.9%
Accounts Payable, Current 2.95M USD +30.7%
Employee-related Liabilities, Current 14.8M USD +69%
Accrued Liabilities, Current 34.8M USD +35.6%
Liabilities, Current 203M USD +573%
Operating Lease, Liability, Noncurrent 1.43M USD +67.3%
Other Liabilities, Noncurrent 2.26M USD -13.6%
Liabilities 347M USD +10.9%
Retained Earnings (Accumulated Deficit) -965M USD -6.95%
Stockholders' Equity Attributable to Parent -201M USD -34.8%
Liabilities and Equity 146M USD -10.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 11.1M USD
Net Cash Provided by (Used in) Financing Activities -280K USD -109%
Net Cash Provided by (Used in) Investing Activities -32K USD +99.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 57.3M shares +4.57%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.8M USD +8.02%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.93M USD +63.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.5M USD +27.5%
Operating Lease, Liability, Current 400K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 10.3M USD -26.6%
Interest Expense 18.9M USD +6.05%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%